Comparative Bioavailability of Two Tablet Formulations of Dipyridamole in Healthy Volunteers

AuthorDavood Beikien
AuthorMohsen Aminien
AuthorReza Dowlatabadien
AuthorMorteza Piralien
Issued Date2003-10-31en
AbstractThe bioavailability of two dipyridamol tablet formulations of (Dipyridamole from Tolidaru and Persantin from Boehringer) was compared in 14 healthy male volunteers who received a single dose of 25 mg of the test (T) and the reference (R) products in a randomized balanced 2- way crossover design. Plasma samples were obtained over a 16 h interval and dipyridamole concentrations determined by HPLC with ultraviolet detection. The maximum plasma concentration (Cmax), area under the plasma concentration time curve up to the last measurable concentration (AUC0-t), as well as infinity (AUC0-∞), and the absorption rate (Cmax/AUC0-∞) were analyzed statistically under the assumption of a multiplicative model. The time to maximum concentration (Tmax) was analyzed assuming an additive model. The parametric confidence intervals (90%) of the mean values of the pharmacokinetic characteristics for T/R ratio were in each case well within the bioequivalence acceptable range of 80-125%. The test formulation was found bioequivalent to the reference formulation by the Schuirmann’s two one-sided t tests and by Wilcoxon Mann Whitney two one-sided tests procedure. Therefore, the 2 formulations were considered to be equivalent.en
DOIhttps://doi.org/10.22037/ijpr.2010.58en
URIhttps://brieflands.com/journals/ijpr/articles/127973en
KeywordBioequivalenten
KeywordPharmacokinetic parametersen
KeywordComparative bioavailabilityen
KeywordDipyridamoleen
PublisherBrieflandsen
TitleComparative Bioavailability of Two Tablet Formulations of Dipyridamole in Healthy Volunteersen
TypeResearch Articleen

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
article_58_c020ec0b8fe53db0e9efad50d3ee292f.pdf
Size:
36.19 KB
Format:
Adobe Portable Document Format
Description:
Article/s PDF